ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of “Buy” by Analysts

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) has been given a consensus rating of “Buy” by the eight brokerages that are currently covering the company, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $18.29.

Several research firms have recently weighed in on ORIC. Stifel Nicolaus began coverage on ORIC Pharmaceuticals in a research note on Friday, September 6th. They set a “buy” rating and a $20.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research note on Monday. Wedbush reiterated an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Tuesday, September 10th. Finally, Oppenheimer dropped their target price on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ORIC Pharmaceuticals by 162.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after purchasing an additional 3,188 shares during the last quarter. Quest Partners LLC grew its stake in shares of ORIC Pharmaceuticals by 253.2% during the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after acquiring an additional 7,440 shares during the period. Creative Planning bought a new position in shares of ORIC Pharmaceuticals in the third quarter worth approximately $116,000. ProShare Advisors LLC purchased a new stake in ORIC Pharmaceuticals in the 1st quarter worth $161,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in ORIC Pharmaceuticals by 71.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock valued at $139,000 after purchasing an additional 5,646 shares during the period. 95.05% of the stock is owned by hedge funds and other institutional investors.

ORIC Pharmaceuticals Trading Up 0.7 %

ORIC opened at $9.48 on Tuesday. ORIC Pharmaceuticals has a twelve month low of $5.85 and a twelve month high of $16.65. The company has a fifty day moving average of $9.72 and a 200-day moving average of $9.25.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). As a group, analysts forecast that ORIC Pharmaceuticals will post -1.8 EPS for the current year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.